← All diseases
Liver, kidneys and digestion
Fatty liver disease (MASH/NASH), advanced
Do you want to receive a message when there is new research about Liver Fat (MASH/NASH), advanced? This is possible with an account. Create a free account or log in.
Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence
Read in plain language what each study is about? With Premium, a single sentence appears above each publication explaining what was studied — and you'll be notified as soon as new research on Liver Steatosis (MASH/NASH), Advanced is available. View what Premium costs.
Publications and studies (2544)
- Spatiotemporal burden, risk factors, and genetic causality of non-alcoholic fatty liver disease and type 2 diabetes mellitus comorbidity in Europe: A multi-database analysis. (2026/03/01) ♡
- Nuclear Factor I-B Delays Liver Fibrosis by Inhibiting Chemokine Ligand 5 Transcription. (2026/03/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Non-alcoholic Fatty Liver Disease in Pregnancy: Clinical Implications, Adverse Outcomes, and Therapeutic Considerations. (2026/03/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Biomarkers in Metabolic Dysfunction-Associated Steatotic Liver Disease. (2026/03/01) ♡
- Bioactive polymethoxylated flavones from Clerodendranthus spicatus alleviate high-fat diet-induced lipid dysfunction and metabolic inflammation via targeting the PPARα/NF-κB pathway. (2026/03/01) ♡
- Sanren Decoction Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease by Protecting Mitochondrial Function. (2026/03/01) ♡
- Unraveling the potential mechanisms of Bupleuri Radix-Scutellariae Radix herb pair on non-alcoholic fatty liver disease by integrated transcriptomics, metabolomics and network pharmacology. (2026/03/01) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. [Mechanism of Shuxiong Prescription in treating non-alcoholic fatty liver disease in rats based on theory of "treatment of different diseases with same approach"]. (2026/03/01) ♡
- Identification and characterization of anti-NAFLD peptides from fish maw using in silico analysis, molecular docking, and DFT quantum calculation. (2026/02/28) ♡
- A novel Fucose-specific lectin from Morchella esculenta modulates gut-liver Axis to alleviate non-alcoholic fatty liver disease. (2026/02/28) ♡
- Ling-Gui-Zhu-Gan decoction improves hepatic steatosis through ALKBH1-mediated DNA N(6)-methyladenosine modification. (2026/02/28) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Fibrotic MASH resolution(VCTE) index to diagnose fibrotic MASH resolution and predict LREs: A global multicenter study. (2026/02/13) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Revealing action mechanisms of Xiaoyaosan decoction for the treatment of nonalcoholic fatty liver in mice employing tandem mass tag quantitative proteomics. (2026/02/07) ♡
- Identification of dinner dietary patterns and their association with metabolic risk factors and anthropometric indices in adults with non-alcoholic fatty liver disease. (2026/02/05) ♡
- Postoperative outcomes in living donor liver transplant vs. deceased donor liver transplant in patients with metabolic dysfunction-associated steatohepatitis: a UNOS database analysis. (2026/02/01) ♡
- Examining Biomarkers for Dyslipidemia, Diabetes, and NAFLD by CDC's 2022 Extended BMI Percentiles in US Youth Aged 6-17 Years. (2026/02/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Modern Diets, Metabolic Inequity, and Race-Ethnic Disparities: Unraveling the Associations With MASLD and Cancer Risk. (2026/02/01) ♡
- Myeloid AEG-1/MTDH drives inflammation and hepatocellular dysfunction in diet-induced steatohepatitis. (2026/02/01) ♡
- Serum Lipidome as a Predictor of Significant Liver Fibrosis in Patients with Severe Obesity Undergoing Bariatric Surgery. (2026/02/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Gut microbiota's role in NAFLD- and HBV/HCV-related hepatocellular carcinoma: Mechanisms and therapeutic implications. (2026/02/01) ♡
- Invited: Longitudinal Assessment of Diets with Varying Carbohydrate-to-Fat Ratios and Fiber Supplementation on Immunometabolic Markers, Liver Function, and Gut Microbiome. (2026/02/01) ♡
- Quinoa bran terpenoids ameliorates metabolic dysfunction-associated steatotic liver disease by enriching of L. murinus LQ719. (2026/02/01) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Mutation of PXR phosphorylation motif at Ser347 disrupts lipid and bile acid homeostasis in diet-induced metabolic dysfunction-associated steatohepatitis in mice. (2026/02/01) ♡
- Hyperimonates A and B, a pair of unprecedented polyprenylated acylphloroglucinols from Hypericum monogynum: Structural elucidation, total synthesis, and lipid-lowering activity. (2026/02/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Metabolic Dysfunction-Associated Steatotic Liver Disease in Pregnancy: A Review. (2026/02/01) ♡
- Randomized researchiParticipants were divided into groups by lottery and compared with each other. This reduces the chance that a difference is due to something other than the treatment. Efficacy and serum metabolomic analysis of Jiu Wei Qingzhi Formula in treating non-alcoholic fatty liver disease: study protocol for a parallel-armed, randomized controlled trial. (2026/02/01) ♡
- Zexie-Baizhu herb pair attenuates MASH via the gut-liver Axis by suppressing NLRP3 Inflammasome activation and M1-macrophage polarization. (2026/02/01) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Baitouweng Tang alleviates dextran sulfate sodium-induced ulcerative colitis in mice: a network pharmacology combined with experimental study. (2026/02/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Ilex cornuta: A review of botany, quality control, phytochemistry, and multimodal pharmacological actions. (2026/01/30) ♡
- Nelumbinis Plumula attenuates high-fat-induced inflammation in non-alcoholic fatty liver through the NOX/NF-κB pathway. (2026/01/30) ♡
- Bioactive compounds and multitarget action mechanism of Erzhi pills in alleviating metabolic dysfunction-associated steatohepatitis. (2026/01/30) ♡
- Association between metabolic dysfunction-associated fatty liver disease and cardiovascular autonomic neuropathy in type 2 diabetes. (2026/01/28) ♡
- TyG index and MAFLD severity are associated with subclinical LV dysfunction in T2DM patients: a cross-sectional study. (2026/01/27) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. An experimental study on shrimp bioactive peptides restoring testicular function in a rat model of fatty liver disease via autophagy, redox balance, and energy transporters. (2026/01/27) ♡
- Curcumin alleviates non-alcoholic fatty liver disease by modulating inflammation, barrier function, and gut microbiota. (2026/01/25) ♡
- Targeting G-protein-coupled receptors and gut microbiota: Ge-Lian Qi-Shen decoction elevates GLP-1 to combat non-alcoholic fatty liver disease. (2026/01/24) ♡
- MASH and the race for liver antifibrotics. (2026/01/23) ♡
- Hepatic adaptation to chronic metabolic stress primes tumorigenesis. (2026/01/22) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Nuclear receptor-driven immunometabolic crosstalk: immune-centric pharmacology targeting the inflamed nexus. (2026/01/21) ♡
- A new lanostane-type triterpene with lipid-lowering activity from Ganoderma lucidum and an additional analogue. (2026/01/21) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Recent advances in non-alcoholic steatohepatitis-associated hepatocellular carcinoma: immune cells, metabolic dysregulation, and therapeutic strategies. (2026/01/21) ♡
- The association between triglyceride glucose-waist-to-height ratio and non-alcoholic fatty liver disease in adults aged over 60 in the United States: a cross-sectional study. (2026/01/21) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Effect of SGLT-2 inhibitors on liver fibrosis progression in patients with MASLD: an updated meta-analysis based on RCTs. (2026/01/20) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. The interactions between autophagy and immune in the liver-adipose-ovary circuit of polycystic ovary syndrome. (2026/01/20) ♡
- Global trends and forecasts of nonalcoholic steatohepatitis causing liver cancer incidence and deaths. (2026/01/19) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Synergistic therapeutic strategies for metabolic dysfunction-associated steatohepatitis and type 2 diabetes mellitus: molecular insights and clinical advances. (2026/01/19) ♡
- Hyperoside attenuates NASH-associated liver fibrosis by modulating Flot2/TLR4 signaling and pyroptosis. (2026/01/15) ♡
- Pyridoxamine reduces inflammatory and microcirculatory abnormalities in metabolic dysfunction-associated steatohepatitis and modulates key factors in the hepatic AGE/ALE signaling pathway. (2026/01/15) ♡
- Piperine-loaded solid lipid nanoparticles: a promising nano-phytomedicine for the treatment of non-alcoholic fatty liver disease. (2026/01/14) ♡
- Systematic reviewiAll research on one question is searched according to fixed rules and compared side by side, so that no studies with poor outcomes are missed. Glomerular hyperfiltration defined by eGFR and long-term clinical outcomes: a systematic review and meta-analysis. (2026/01/13) ♡
codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.